ArticlePragmatic and observational research2017
The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship.
Article in Pragmatic and observational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- SGLT2 Inhibitors and Asthma Exacerbation Risk Among Patients With Type 2 Diabetes and Asthma: A Target Trial Emulation.Clinical pharmacology and therapeutics · 2026Article
- Type 2 Diabetes and the Lung - Cause and Consequence.Current diabetes reports · 2026Review
- Glucagon-Like Peptide-1 Receptor Agonists vs Dipeptidyl Peptidase-4 Inhibitor Use on Risk of Asthma Exacerbation Among Diabetic Patients with Co-Morbid Asthma in Hong Kong.Journal of asthma and allergy · 2026Article
- Diabetes-inducing effects of bronchial asthma.World journal of diabetes · 2025Article
- Unraveling the Link between Ιnsulin Resistance and Bronchial Asthma.Biomedicines · 2024Review
- Development of the dipeptidyl peptidase 4 family and its association with lung diseases: a narrative review.Journal of thoracic disease · 2023Review
- Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity.Pulmonary therapy · 2023Review
- Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives mInternational journal of oncology · 2023Article
- Article
- Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.American journal of respiratory and critical care medicine · 2021Article
- The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.Frontiers in pharmacology · 2021Review
- Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes.International journal of environmental research and public health · 2019Article
- Diabetes and Lung Disease: A Neglected Relationship.The review of diabetic studies : RDS · 2019Review
- Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleDPP-4 may regulate immunological pathways implicated in asthma. Assessing whether DPP-4 inhibitor (DPP-4i) use might affect asthma control is clinically important because DPP-4i use in type 2 diabetes mellitus management (T2DM) is increasing. This study evaluated associations between DPP-4i use and asthma control.
methodsThis was a retrospective, observational, matched cohort study using administrative claims in the MarketScan
resultsThe adjusted odds of achieving RDAC (odds ratio [OR]: 1.05; 95% CI: 0.964 to 1.147), overall asthma control (OR: 1.04; 95% CI: 0.956 to 1.135), and treatment stability (OR: 1.04; 95% CI: 0.949 to 1.115) did not differ between the DPP-4i and non-DPP-4i cohorts. A difference was not found between cohorts in severe asthma exacerbation rates during the 12 months following initiation of antidiabetes treatment (mean = 0.32 vs. 0.34 exacerbations per subject-year, respectively;
conclusionAsthma control was similar between patients initiating DPP-4i and non-DPP-4i antidiabetes medications, suggesting no association between DPP-4i use and asthma control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.